Pharmaceutical stocks a brother impact 450 billion market value, Kantai, Meirui soared by more than 50%!

Pharmaceutical Network May 26, 2017 in the A-share market, there have been Hengrui Pharmaceuticals, Kangmei Pharmaceuticals, Yunnan White Medicine, Shanghai Laishi and other 600 billion market value of pharmaceutical stocks in the peak periodIn December 2018, the market value of 100 billion is the only Hengrui PharmaceuticalsSince the beginning of this year, pharmaceutical stocks continued to rise, Hengrui Pharmaceuticals, Changchun Gaoxin, Renfu Pharmaceuticals, Huahai Pharmaceuticals and many other pharmaceutical stocks hit a new highUp to now, pharmaceutical stocks TOP10, Hengrui Pharmaceuticals, Murray Medical, Pharmaceutical Mingkang and other 7 pharmaceutical stock market value of more than 100 billion scale, and Kantai Biological, Film, Fosun Pharma are expected to join the ranks of 100 billion market valueIn addition, Kantai Bio, Zhifei Bio, Murray Medical soared by more than 50%Pharmaceutical Stock Market value TOP10
Note: In terms of closing price, May 25 is Hengrui Pharmaceuticals de-right (interest) dayHengrui Pharmaceutical: In June 2018, Hengrui Pharmaceuticals became the first pharmaceutical stocks with a market value of more than 300 billion yuan; In October 19, the market value exceeded the 400 billion mark; on May 21, 2020, its share price briefly broke through the 100 yuan mark, approaching 450 billion yuan; and as of May 25, the market value fell back to 429.6 billion yuanOver the years, Hengrui Pharma adheres to the strategy of research and development innovationAt the end of 2019, Hengrui Pharma announced that it would stop most of its generic selling projects and focus on the development of innovative and valuable high-end generic semodels to achieve differentiated competition and output for pharmaceutical productsSince May this year, Hengrui Pharmaceuticals has issued a number of announcements related to drug research and development, including a number of drugs approved for clinical use of toluene sulfonate remagine, ialitacid fentanyl capsules, fluoropine Pali capsules and other drugs approved for clinical use;Murray Healthcare: In October 2018, Murray Medical officially landed on A-shares, and one year after listing, the market value exceeded the 200 billion mark, and by May 25, 2020, the market value was 339.2 billion yuan, a market value of more than 100 billion yuan compared with 2019, making it the second-largest pharmaceutical company in the marketThroughout, Murray Medical continues to promote platform, high-end, globalizationIn 2019, the company achieved revenue of RMB16.556 billion and net profit of RMB4,681 million, with a year-on-year growth of more than 20%This year by the impact of the outbreak of new coronapneumonia, related demand-driven performance growth, monitor, ventilator, portable color super, mobile DR and other instruments and outbreak-related products have increased to varying degrees, of which, life information and support line pull is particularly significantIn the first quarter of this year, the company achieved revenue of RMB4,741 million, up 21.39% YoY, and net profit of RMB1.313 billion, up 30.58% YoY Some brokerage analysis pointed out that the second quarter of Murray Medical is expected to usher in "capacity expansion , domestic conventional demand recovery and overseas anti-epidemic demand" of multiple benefits, while the company at home and abroad during the outstanding performance of anti-epidemic, is also expected to be positive role in the company's brand image and customer awareness of the promotion 　　Kantai Bio: In February 2017, Kantai Bio landed in the A-share market Its main business for human vaccine research and development, production and sales, has been listed for sale of products with cell white b influenzae type b joint vaccine, recombinant hepatitis B vaccine (brewing yeast) and so on, product categories covering immunization program vaccine and non-immune program vaccine In 2019, Kantai Bio achieved revenue of RMB1,943 million and net profit of RMB575 million, up 31.86 percent Year-on-Year In the first quarter of this year, the company's revenue was RMB177 million, down 48.12% YoY, and net profit was RMB2.42 million, down 97.57% YoY Broker analysis pointed out that as the epidemic is gradually controlled, the impact will be gradually eliminated, vaccination sites to resume scheduled vaccination, the second quarter of the results are expected to have a restorative growth In addition, the company's two major heavyweights have made progress in the research varieties: 13-price pneumonia combined seedlings have been submitted for listing applications and included in the priority review, is expected to be listed at the end of this year or early next year; After the listing of heavy-duty varieties, the company's performance is expected to usher in an outbreak As of the close of trading on May 25, 2020, Kantai Bio had a market value of 98.1 billion yuan tablets: the company's main business includes pharmaceutical manufacturing and pharmaceutical circulation, the core products for the tablet series of products, including tablets, tablet capsules, compound tablets, such as tablets and other sashimi products In 2019, the company's revenue and net profit grew by more than 20%, and in the first quarter of this year, revenue was RMB1,714 million, up 15.51% YoY, and net profit was RMB468 million, up 15.69% YoY The company closely around the main industry, brand as the flag, capital as the link, and actively expand to the industrial chain upstream and downstream, the formation of a "one nuclear two wings" strategic development pattern, and strive to build a pharmaceutical manufacturing and production as a leader, , and characteristic seefficiency , daily products as two wings, to the pharmaceutical circulation as a supplement to the large health industry group, the film into a strong Chinese medicine cultural value, a large domestic health brand Fosun Pharma: This year affected by the outbreak, the company's performance declined year-on-year, but with the outbreak under control, innovative research and development of frequent news, its performance will gradually recover It is worth noting that Fosun Pharma has made progress in the development of a number of innovative drugs, among which, Avalopa tablets were approved for listing, CAR-T submitted listing applications and included in the priority review In addition, the FourGretin Public Phase III clinical, PD-1 publicity for head and neck tumors, such as Phase II clinical, a total of 4 new drugs or new indications in the market application, more than 10 Phase III clinical is advancing A few days ago, Fosun Pharma issued a notice, holding subsidiary Shanghai Fuhong Hanxuan Biopharmaceutical Co., Ltd received the "Notice of Acceptance", its rituxiximono injection (i.e., recombinant human rat chimeric anti-CD20 monoclonal antibody injection, commodity name Hanlikang) added two new indications by the State Drug Administration registration review industry analysts pointed out that this year
stocks hit new highs, on the one hand, the annual report and the disclosure of the quarterly report, many individual stock performance reached or even exceeded expectations; source: Oriental Wealth Network, listed companies announcement note: if there are omissions, welcome to point the finger!